AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that it has received written confirmation from the Centers for Medicare & ...
AUSTIN, Texas--(BUSINESS WIRE)-- Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now broadly ...
Natera recently reported a series of advances, including an upgraded multi-modal Signatera MRD model, expanded AI ...
Natera Inc. (NASDAQ: NTRA) on Wednesday revealed initial translational research results from the international randomized Phase 3 PALLAS study. Data were presented at the San Antonio Breast Cancer ...
Genetic testing company Natera (NASDAQ:NTRA). reported Q1 CY2025 results , with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue guidance of $1.98 billion at the midpoint ...
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the results of a study led by Stanford University School of Medicine for the evaluation of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results